Paper39770542
Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy.
Mihaylova R and 3 others. Pharmaceuticals (Basel), 2024. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy. Papers, record 39770542. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39770542
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| project № BG-RRP-2.004-0004-C01 | European Union's NextGenerationEU economic recovery package via the National Recovery and Resilience Plan of the Republic of Bulgaria | PubMed |
Source PubMed
References235
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38179054 | Targeting Trop2 in solid tumors: a look into structures and novel epitopes. | Front Immunol | 2023 | https://conductscience.org/library/papers/38179054 | PubMed |
| 2 | 37218076 | Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment. | Oncologist | 2023 | https://conductscience.org/library/papers/37218076 | PubMed |
| 3 | 32943087 | BCMA-targeted immunotherapy for multiple myeloma. | J Hematol Oncol | 2020 | https://conductscience.org/library/papers/32943087 | PubMed |
| 4 | 32305312 | An overview on anti-tubulin agents for the treatment of lymphoma patients. | Pharmacol Ther | 2020 | https://conductscience.org/library/papers/32305312 | PubMed |
| 5 | 38007239 | Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas. | J Immunother Cancer | 2023 | https://conductscience.org/library/papers/38007239 | PubMed |
| 6 | 38758596 | The Evolution of Antibody-Drug Conjugates: Toward Accurate DAR and Multi-specificity. | ChemMedChem | 2024 | https://conductscience.org/library/papers/38758596 | PubMed |
| 7 | 28138156 | Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. | Immunol Cell Biol | 2017 | https://conductscience.org/library/papers/28138156 | PubMed |
| 8 | 38639400 | AJICAP-M: Traceless Affinity Peptide Mediated Conjugation Technology for Site-Selective Antibody-Drug Conjugate Synthesis. | Org Lett | 2024 | https://conductscience.org/library/papers/38639400 | PubMed |
| 9 | 20108971 | Cancer therapies utilizing the camptothecins: a review of the in vivo literature. | Mol Pharm | 2010 | https://conductscience.org/library/papers/20108971 | PubMed |
| 10 | 27913999 | The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. | Cancer Metastasis Rev | 2016 | https://conductscience.org/library/papers/27913999 | PubMed |
| 11 | 38704241 | Antibody-drug conjugates in solid tumors; new strategy for cancer therapy. | Jpn J Clin Oncol | 2024 | https://conductscience.org/library/papers/38704241 | PubMed |
| 12 | 31628266 | Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia. | Oncologist | 2020 | https://conductscience.org/library/papers/31628266 | PubMed |
| 13 | 16990856 | Topoisomerase I inhibitors: camptothecins and beyond. | Nat Rev Cancer | 2006 | https://conductscience.org/library/papers/16990856 | PubMed |
| 14 | 22811920 | Acute Liver Failure Caused by Amanita phalloides Poisoning. | Int J Hepatol | 2012 | https://conductscience.org/library/papers/22811920 | PubMed |
| 15 | 29901160 | Trop2 is a potential biomarker for the promotion of EMT in human breast cancer. | Oncol Rep | 2018 | https://conductscience.org/library/papers/29901160 | PubMed |
| 16 | 37896162 | Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/37896162 | PubMed |
| 17 | 36894324 | AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production. | Bioconjug Chem | 2023 | https://conductscience.org/library/papers/36894324 | PubMed |
| 18 | 35094917 | Emerging roles for folate receptor FOLR1 in signaling and cancer. | Trends Endocrinol Metab | 2022 | https://conductscience.org/library/papers/35094917 | PubMed |
| 19 | 23462379 | Ribosome-inactivating proteins: from toxins to useful proteins. | Toxicon | 2013 | https://conductscience.org/library/papers/23462379 | PubMed |
| 20 | 38439551 | Biparatopic antibodies: therapeutic applications and prospects. | MAbs | 2024 | https://conductscience.org/library/papers/38439551 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42185658 | Antibody-drug conjugates in cancer therapy: do we need biomarkers? A comprehensive review. | Cancer Metastasis Rev | 2026 | https://conductscience.org/library/papers/42185658 | PubMed |
| 42043624 | Antibody-Drug Conjugates Reshape the Landscape of Cancer Therapy: Evolution, Challenges and Future Perspectives from the Concept of "Magic Bullet" to Clinical Application. | Curr Oncol Rep | 2026 | https://conductscience.org/library/papers/42043624 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39770542
GET https://conductscience.org/api/papers/v1/39770542/references?page=2